Skip to main content
Nathan Bahary, MD, Oncology, Pittsburgh, PA

NathanBaharyMDPhD

Oncology Pittsburgh, PA

Gastrointestinal Cancer

Academic Chief of Medical Oncology—AHN Cancer Institute Director of AHNCI Research

Dr. Bahary is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Bahary's full profile

Already have an account?

Summary

  • Dr. Nathan Bahary is an oncologist in Pittsburgh, PA. He received his medical degree from Weill Cornell Medicine and has been in practice 28 years. He specializes in gastrointestinal cancer and is experienced in gastrointestinal oncology, general medical oncology, and pancreatic neoplasms.

Education & Training

  • Dana-Farber Cancer Institute
    Dana-Farber Cancer InstituteMedical Oncology, 1997 - 2002
  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1995 - 1998
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1992 - 1995
  • Rockefeller University
    Rockefeller UniversityPhD, Molecular Genetics, 1987 - 1992
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 1989

Certifications & Licensure

  • WV State Medical License
    WV State Medical License 2022 - 2024
  • OH State Medical License
    OH State Medical License 2022 - 2024
  • NY State Medical License
    NY State Medical License 2022 - 2024
  • PA State Medical License
    PA State Medical License 2002 - 2024
  • MA State Medical License
    MA State Medical License 1994 - 2003
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

  • National Drug Shortage Impacting Cancer Care at UPMC
    National Drug Shortage Impacting Cancer Care at UPMCMay 25th, 2023
  • Despite Challenging Statistics, ‘Jeopardy!’ Host Alex Trebek Vows to Fight Pancreatic Cancer
    Despite Challenging Statistics, ‘Jeopardy!’ Host Alex Trebek Vows to Fight Pancreatic CancerMarch 7th, 2019
  • Genomics Could Better Match Treatments to Pancreatic Cancer Patients
    Genomics Could Better Match Treatments to Pancreatic Cancer PatientsMarch 4th, 2019
  • Join now to see all

Professional Memberships